Group 1 - The core viewpoint of the article highlights that Hengan International's stock has risen over 3% following the release of its interim results, indicating positive market sentiment despite a slight decline in revenue and profit [1] - For the six months ending June 30, 2025, Hengan International reported revenue of 11.808 billion RMB, a year-on-year decrease of 0.2%, and a profit attributable to equity holders of 1.373 billion RMB, down 2.6% year-on-year [1] - The company maintained an interim dividend of 0.7 RMB per share, reflecting a commitment to returning value to shareholders despite the slight decline in profits [1] Group 2 - Hengan International expects steady growth in tissue sales in the second half of 2025, which will support overall revenue stability [1] - The company anticipates that its strategies in omni-channel sales, product personalization, and stable pricing will contribute to maintaining revenue stability [1] - Hengan plans to increase marketing resource allocation in the second half of 2025, with expectations for high-end, high-margin products to continue stable growth, supported by stable raw material prices [1]